“Sculptra side effects” and “Sculptra bad before and after” are, between them, the most-searched safety questions about this injectable — together with “gone wrong”, “nodules” and “lumps”, about 7,000 US searches a month (clickstream estimate, October 2026). This page answers them with counts from the trials and from FDA's device-report database, read on 15 October 2026. It does not show photographs, because a photograph cannot say how often something happens. It is not advice about treatment: whether anyone is treated, and what to do about a problem afterwards, is a decision for a qualified clinician. What Sculptra is, and its approval history, are on our Sculptra explainer.
What the risks are, in FDA's own list
FDA's consumer page on dermal fillers, which covers Sculptra alongside hyaluronic-acid and calcium-based products, lists the risks of approved uses (fda.gov, content current as of 6 July 2023). Among them: bruising, redness, swelling, pain and itching; delayed swelling or redness after a viral or bacterial illness, a vaccination or a dental procedure; “raised bumps in or under the skin (nodules or granulomas) that may need to be treated with injections, oral antibiotics, or surgically removed”; infection; open or draining wounds; allergic reaction; and necrosis. On injection into a blood vessel, the page says the chances are low but that complications “can be serious and may be permanent”, including vision abnormalities, blindness and stroke.
That list describes fillers as a class. The rest of this page asks what has actually been recorded for Sculptra.
Lumps over five years: the largest count
The biggest safety record for poly-L-lactic acid is Sculptra's five-year post-approval study, run by Galderma and posted to the registry (NCT02425943). It treated 867 people once for nasolabial folds and other facial wrinkles and reported adverse events for the full five years, listing any event that reached a 1% threshold. Its table separates two kinds of lump:
| Event in the registry table | Skin types I–III (557) | Skin types IV–VI (310) |
|---|---|---|
| Implant-site papules | 101 (18.1%) | 42 (13.5%) |
| Implant-site nodules | 95 (17.1%) | 43 (13.9%) |
| Implant-site pain | 9 (1.6%) | 4 (1.3%) |
| Implant-site discolouration | 1 (0.2%) | 5 (1.6%) |
Percentages are our arithmetic from the posted counts. A papule is a small raised bump; a nodule is a larger, firmer lump under the surface. The table gives participants with at least one event, so a person can appear in both rows, and the two rows cannot simply be added. Nor does it say how long each lump lasted or whether it needed treatment.
The serious events are a different picture. The table lists 39 participants with a serious event among skin types I–III and 11 among types IV–VI, and most of its 59 entries are illnesses that occur in any adult population followed for five years: eleven kinds of cancer, fractures, infections such as pneumonia and appendicitis, three deaths. Four entries sit closer to the injections. Two are granulomas (one coded “granuloma”, one “granuloma skin”), one is a retinal artery occlusion — the blood-vessel event behind the vision warnings on filler labels — and one is an anaphylactic reaction, each in a single participant with skin type I–III. The registry does not say which events investigators judged related to the injections, so none of them can be read as a confirmed device effect from this table alone; equally, none can be dismissed.
The 2023 cheek trial
The trial behind Sculptra's 2023 cheek-wrinkle approval reported adverse events at a 5% threshold for its first year (NCT04124692). Only one event cleared it: injection-site bruising, 11 of 97 treated participants. No nodule or papule row appears, which means fewer than about five treated participants had one listed in that year, not that none did. The serious events in the treated group are reported on our Sculptra page. One year of follow-up is also shorter than the window in which delayed lumps are described.
What FDA's device reports describe since mid-2023
Manufacturers, clinicians and patients can all file a device problem with FDA, and the filings land in a public database called MAUDE. To see what has been reported since the cheek approval widened Sculptra's use, we counted reports received from 1 June 2023 to 15 October 2026 through FDA's public interface (openFDA). There were 189, and every one was classed as an injury report rather than a malfunction.
| Patient problem coded | Reports, Jun 2023 – 15 Oct 2026 |
|---|---|
| Subcutaneous nodule | 78 |
| Granuloma | 33 |
| Swelling / oedema | 30 |
| Skin inflammation / irritation | 18 |
| Skin infection | 17 |
| Foreign body reaction | 16 |
| Allergic reaction | 16 |
| Abscess | 15 |
| Scar tissue | 12 |
| Deformity / disfigurement | 10 |
| Cellulitis | 8 |
| Obstruction / occlusion | 7 |
One report can carry several codes, so the rows add to more than 189. The yearly totals were 38 in 2023, 42 in 2024 and 40 in 2025, and 83 had been received in 2026 by mid-October. The database cannot say why 2026 is higher: wider use after the cheek approval, a change in how reports are filed, or more problems are all possible, and nothing in MAUDE separates them. It also records no denominator — nobody knows from this source how many treatments the 189 reports came from — so none of these numbers is a rate.
Two more limits travel with every MAUDE figure. A report is an allegation that may be incomplete, duplicated or unrelated to the device. And the count is dominated by what gets reported: a lump that settles is less likely to reach FDA than one that needs surgery. How these reports compare with Radiesse's, which lean towards vascular events rather than lumps, is set out on our Sculptra vs Radiesse page.
Why lumps are the characteristic problem
Poly-L-lactic acid works by provoking a slow tissue response around particles that stay in the skin for months, which is also why its typical complication is a lump rather than an immediate one. Clinicians describe two broad kinds in the literature: small, early nodules thought to come from particles clumping or sitting too superficially, and later inflammatory granulomas. A PubMed search on 15 October 2026 for Sculptra or poly-L-lactic acid with nodules, granulomas or papules returned 152 records, most of them case reports, series and reviews rather than controlled comparisons. That body of work is why reconstitution volumes rose over the years and why technique, rather than the product alone, is discussed as a cause; whether the old “5-5-5” massage rule helps has been tested once, with a small randomized trial covered on our Sculptra page.
Because the particles are not a gel, there is no enzyme that dissolves them. That is the practical difference from a hyaluronic-acid filler, discussed on our Sculptra vs filler page, and the reason FDA's list mentions injections, antibiotics and surgery for persistent lumps.
What the record does not show
It does not show how often any one injector's patients develop lumps, because the trials pooled sites and MAUDE has no denominator. It does not show how many of the nodules in the five-year study resolved on their own, because the posted table gives counts, not outcomes. It does not separate early from late lumps, because the totals cover the whole follow-up. And it does not show results for uses outside the approved face indications, such as the buttocks or neck, which rest on small uncontrolled series — set out on our buttocks page. It does show, more precisely than an online photograph can, that bumps under the skin are the event Sculptra's records return to again and again. How long the cosmetic result lasts is on how long Sculptra lasts.
Sources and dates
Opened 15 October 2026: ClinicalTrials.gov posted adverse-event tables for NCT02425943 (five-year post-approval study, threshold 1%) and NCT04124692 (cheek trial, threshold 5%); FDA MAUDE via the openFDA device event endpoint, device.brand_name:sculptra, counts by patient problem and by date received; FDA's dermal fillers page (content current as of 6 July 2023); PubMed search (sculptra OR "poly-L-lactic acid") AND (nodule* OR granuloma* OR papule*). Percentages are our arithmetic from posted counts. Corrections go to the contact page.